Farxiga Overview 2019: A Member of the Novel Sodium-Glucose Cotransporter-2 (SGLT-2) Inhibitor Class

June 25, 2019 Off By BusinessWire

DUBLIN–(BUSINESS WIRE)–The “Farxiga” drug pipelines has been added to ResearchAndMarkets.com’s offering.

Farxiga (dapagliflozin; AstraZeneca/Ono Pharmaceutical) is a member of the novel sodium-glucose cotransporter-2 (SGLT-2) inhibitor class.

It is approved for the treatment of type 2 diabetes and currently in Phase III trials for the treatment of type 1 diabetes, as well as for chronic kidney disease including diabetic nephropathy. SGLT-2 inhibitors do not target insulin secretion or sensitivity and do not interfere with glucose metabolism.

They prevent filtered glucose from being reabsorbed in the kidney rather than actively facilitating glucose filtration and excretion. Due to this distinct mechanism of action, when SGLT-2 inhibitors are used as monotherapy, they do not lower glucose to unsafe levels and thus avoid the risk of hypoglycemia.

Key Topics Covered:

OVERVIEW

Drug Overview
Product Profiles
Farxiga : Diabetic nephropathy
Farxiga : Diabetes type 1
Farxiga : Chronic heart failure (CHF)
Farxiga : Diabetes type 2

LIST OF FIGURES

The authors drug assessment summary of Farxiga for diabetic nephropathy
The authors drug assessment summary of Farxiga for diabetic nephropathy
Farxiga sales for diabetic nephropathy across the US, Japan, and five major EU markets, by country, 2017-26
Farxiga for type 1 diabetes – SWOT analysis
The authors drug assessment of Farxiga in type 1 diabetes
The authors drug assessment of Farxiga in type 1 diabetes
Farxiga for chronic heart failure – SWOT analysis
The authors drug assessment summary of Farxiga for chronic heart failure
The authors drug assessment summary of Farxiga for chronic heart failure
Farxiga sales for chronic heart failure across the US, Japan, and five major EU markets, by country, 2017-26
Farxiga for type 2 diabetes – SWOT analysis
The authors drug assessment of Farxiga
The authors drug assessment scorecard for Farxiga compared to Januvia
Farxiga sales for type 2 diabetes across the US, Japan, and five major EU markets, by country, 2016-25
Xigduo sales for type 2 diabetes across the US, Japan, and five major EU markets, by country, 2016-25

LIST OF TABLES

Farxiga drug profile
Farxiga Phase III trial in chronic kidney disease, including diabetic nephropathy
Farxiga Phase II/III trial on UACR and glycemic control in diabetic nephropathy
Farxiga for diabetic nephropathy – SWOT analysis
Farxiga drug profile
Farxiga late-phase trials in type 1 diabetes
Farxiga drug profile
Farxiga Phase III trials in chronic heart failure
Farxiga sales for chronic heart failure across the US, Japan, and five major EU markets, by country ($m), 2017-26
Farxiga franchise products
Farxiga drug profile
Xigduo drug profile
Overview of pivotal trial data for Farxiga in diabetes
Key planned and ongoing Phase III clinical trials for Farxiga in diabetes
Farxiga sales for type 2 diabetes across the US, Japan, and five major EU markets, by country ($m), 2016-25
Xigduo sales for type 2 diabetes across the US, Japan, and five major EU markets, by country ($m), 2016-25